| Trial ID: | L0359 |
| Source ID: | NCT02216877
|
| Associated Drug: |
Mablet 360 Mg
|
| Title: |
Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|Hypomagnesemia
|
| Interventions: |
DRUG: Mablet 360 mg|DRUG: Placebo
|
| Outcome Measures: |
Primary: Intracellular magnesium, Intracellular magnesium measured by energy dispersive x-ray analysis (www.exatest.com)., 8 weeks | Secondary: Total serum magnesium, 8 weeks|Ionized serum magnesium, 8 weeks | Other: Markers of CKD-MBD (Chronic Kidney Disease - Mineral and Bone Disorder), Serum calcium, phosphate, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF-23), 25-(OH)-hydroxy vitamin D, 1,25-(OH)-dihydroxy vitamin D as well as urine calcium and phosphate., 8 weeks
|
| Sponsor/Collaborators: |
Sponsor: Zealand University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2014-08
|
| Completion Date: |
2015-04
|
| Results First Posted: |
|
| Last Update Posted: |
2015-04-28
|
| Locations: |
Department of Medicine, Division of Nephrology, Roskilde County Hospital, Roskilde, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02216877
|
